Sumitomo Seika Chemicals Azioni (OTC: SUMKF)

Ultime notizie per Sumitomo Seika Chemicals (OTC:SUMKF) Azioni

Sumitomo Seika Chemicals Co Ltd manufactures and sells chemicals and chemical-based products in three segments based on product type. The superabsorbent-polymers segment, which generates the majority of revenue, sells diapers, sanitary napkins, water repellent tape for power and optical cables, and sodium polyacrylate products used as a water-retention agent for agricultural and horticultural use. The chemicals segment sells plastic polymers, latex, and chemical additives used in the production of lithium-ion batteries and pharmaceuticals. The gases segment sells gases for industrial use, which includes electronics production, as well as aerosol propellant gas and nitrous oxide.

SUMITOMO SEIKA CHEMICALS by Sumitomo Seika Chemicals Co. Ltd.

Sumitomo Seika Chemicals Co Ltd

Piper Sandler analyst Nathan Race maintains UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight and raises the price target from $142 to $143.

News

Price Target

Analyst Ratings

UMBF

Piper Sandler Maintains Overweight on UMB Financial, Raises Price Target to $143

Piper Sandler analyst Stephen Scouten maintains Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) with a Overweight and raises the price target from $41 to $44.

RNST

Piper Sandler Maintains Overweight on Renasant, Raises Price Target to $44

WIIM

Whirlpool shares are trading lower following a Q4 revenue miss. Also, the company issued FY25 guidance below estimates.

HarborOne Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HONE#NASDAQ">HONE</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is a 122.22 percent increase over earnings of $0.09 per share from the same period last year.

Earnings

HONE

HarborOne Bancorp Q4 EPS $0.20 Beats $0.17 Estimate

CMCSA

Comcast shares are trading lower. The company reported Q4 financial results.

Piper Sandler analyst Nathan Rice maintains Merchants Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIN#NASDAQ">MBIN</a>) with a Overweight and raises the price target from $52.5 to $56.5.

MBIN

Piper Sandler Maintains Overweight on Merchants Bancorp, Raises Price Target to $56.5

United Parcel Service Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) shares are trading lower after the company reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b43330139/ups-releases-4q-2024-earnings-and-provides-2025-guidance" rel="noreferrer noopener">mixed fourth-quarter results</a>.
UPS reported consolidated revenue growth of 1.5% year-over-year to $25.301 billion, missing the consensus of $25.419 billion. Adjusted EPS was $2.75, up 11.3% YoY, <a href="https://www.benzinga.com/earnings">above the consensus of $2.53.</a>
GAAP results include a $639 million charge ($0.74 per share), covering a $506 million pension charge, $73 million in transformation costs, $46 million in asset impairments, and $14 million for pension withdrawal.
Consolidated operating profit reached $2.9 billion, increasing 18.1% from the last year quarter and 11.2% on a non-GAAP adjusted basis. Adjusted operating margin stood at 12.3%, up from 11.2% a year ago.
U.S. Domestic Segment revenue increased 2.2% to $17.312 billion, reflecting a 2.4% increase in revenue per piece and increases in air cargo. The adjusted operating margin stood at 10.1%.
International Segment revenue grew 6.9% to $4.923 billion, reflecting an 8.8% increase in average daily volume. The adjusted operating margin was 21.6%.
Supply Chain Solutions Segment revenue declined by 9.1% to $3.066 billion, driven by the Coyote divestiture, partially offset by growth in air and ocean forwarding. The adjusted operating margin was 9.3%.
UPS&#8217; operating cash flow for fiscal 2024 totaled $10.1 billion, and free cash flow was $6.3 billion. The company returned $5.9 billion to shareholders through dividends and share buybacks.
&#8220;We are making business and operational changes that, along with the foundational changes we&#8217;ve already made, will put us further down the path to becoming a more profitable, agile and differentiated UPS that is growing in the best parts of the market,&#8221; commented Carol Tomé, UPS chief executive officer.
Strategic Actions: The company announced reaching an agreement to reduce volume with its largest customer by over 50% by late 2026, insourcing 100% of UPS SurePost from January 1, 2025, and reconfiguring its U.S. network. Additionally, UPS is launching multi-year &#8220;Efficiency Reimagined&#8221; initiatives, aiming to save $1 billion through an end-to-end process redesign.
2025 Outlook: UPS expects revenue of ~ $89 billion, <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">sharply below the $94.877 billion consensus</a>, and sees an adjusted operating margin of 10.8%.
The company plans $3.5 billion in capital spending, $5.5 billion in dividends (pending approval), $1 billion in share buybacks, and an expected 23.5% tax rate.
Price Action: UPS shares are trading lower by 13.5% at $115.66 premarket at the last check Thursday.
Photo via Shutterstock.

Equities

Large Cap

Guidance

Movers

UPS Q4 Earnings: Major Customer Volume Cut Raises Jitters, Stock Tanks

<a href="https://www.globenewswire.com/Tracker?data=MMYWUYfAGsuNXl2GLahtNQo6Rk9GDlWqpUGtlOchK6uDi223dv2FGXdVRic1GMhy6uY5UU_gjmSeA2JAvs1cnsdjgpjkvP-CM6JXwFaHpKs=">Atossa Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOS#NASDAQ">ATOS</a>) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the prevention and treatment of breast cancer, today issued the following statement in response to the Patent Trial and Appeal Board's (PTAB) final written decision in PGR2023-00043 regarding U.S. Patent No. 11,572,334 (the "'334 patent").
Atossa is disappointed with the PTAB's decision finding all challenged claims in the '334 patent unpatentable and is evaluating its options. This decision has no impact on the formulations currently in clinical development by Atossa. While Atossa disagrees with the decision and believes there are appealable issues, the Company will not be pursuing an appeal from the PTAB decision, given the cost and time involved. Instead, the Company intends to continue to pursue patent protection around the Company's current formulations in clinical development, including in a new Continuation Patent Application to be filed with the U.S. Patent Office.
Atossa is also announcing the issuance of a new patent on January 21, 2025, U.S. Patent No. 12,201,591, entitled, "Sustained Release Compositions of Endoxifen." The 31 claims of this new patent are directed to sustained release compositions of endoxifen.
Atossa's patent estate comprises, among other patent assets, U.S., Patent No. 11,261,151, with 21 claims; U.S. Patent No. 11,680,036, with 22 claims; U.S. Patent No. 12,071,391, with 44 claims; and the newly issued U.S. Patent No. 12,201,591, with 31 claims. These patents provide a comprehensive patent estate that includes claims directed to Atossa's current formulations in clinical development.

ATOS

Atossa Therapeutics Responds To PTAB Decision On Patent '334, Opts Against Appeal; Will File Continuation Patent Application; New Patent Announced For Sustained Release Compositions Of Endoxifen, Effective Jan 2025

Piper Sandler analyst Matthew Clark maintains Hope Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) with a Neutral and lowers the price target from $13 to $12.

HOPE

Piper Sandler Maintains Neutral on Hope Bancorp, Lowers Price Target to $12

International Paper shares are trading lower after the company reported worse-than-expected Q4 financial results.

Offerings

ELTX

Elicio Therapeutics Enters Definitive Securities Purchase Agreement With Institutional Investors For Purchase Of 1,261,830 Shares At $7.925

Piper Sandler analyst Andrew Liesch maintains Capitol Federal Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFFN#NASDAQ">CFFN</a>) with a Neutral and lowers the price target from $7 to $6.5.

CFFN

Piper Sandler Maintains Neutral on Capitol Federal Finl, Lowers Price Target to $6.5

CHKP

Check Point Software shares are trading higher following a Q4 adjusted EPS and revenue beat.

SILC

Silicom Sees FY25 Revenues Between $14M-$15M Vs. $14.37M Estimate; Growth In 2025 Is Expected To Be In The Low Single Digit

Takeda Pharmaceutical shares are trading higher after the company reported better-than-expected Q3 sales results. Also, the company announced a new CEO and share buyback program.

Piper Sandler analyst Alexander Goldfarb maintains BXP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXP#NYSE">BXP</a>) with a Overweight and lowers the price target from $105 to $100.

Piper Sandler Maintains Overweight on BXP, Lowers Price Target to $100

Standard Lithium Ltd. ("Standard Lithium") (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/SLI#TSXV">SLI</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>), a leading near-commercial lithium developer, and Equinor, a global energy leader,&nbsp;today announced Smackover Lithium as the new name for their joint venture developing direct lithium extraction ("DLE") projects in Southwest Arkansas and East Texas.
Smackover Lithium was announced yesterday at a community meeting in Lewisville, Arkansas, home of a planned field office and nearby the joint venture's South West Arkansas ("SWA") project. The SWA project, located in Lafayette and Columbia counties, is expected to be one of the world's first commercial-scale DLE facilities.

TSXV:SLI

Standard Lithium And Equinor Announce Smackover Lithium As New Name For Joint Venture On Direct Lithium Extraction Projects In Southwest Arkansas And East Texas; SWA Project Set To Be World's First Commercial-Scale DLE Facility

Silicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILC#NASDAQ">SILC</a>) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.32) by 81.25 percent. This is a 728.57 percent decrease over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $14.491 million which missed the analyst consensus estimate of $14.635 million by 0.98 percent. This is a 22.77 percent decrease over sales of $18.763 million the same period last year.

Earnings Misses

Silicom Q4 2024 Adj. EPS $(0.58) Misses $(0.32) Estimate, Sales $14.491M Miss $14.635M Estimate

Abu Dhabi Public Health Center To Introduce Blood-Based Colorectal Cancer Screening Program Using Guardant Health's Shield Test

Piper Sandler analyst Andrew Liesch maintains First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) with a Overweight and lowers the price target from $32 to $28.

Comments

Sumitomo Seika Chemicals

Notizie

Ultime notizie per Sumitomo Seika Chemicals (OTC:SUMKF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO